1. Rosenberg WM, Gray JA et al. Evidence based medicine: what it is and what it isn't. BMJ 1996, January; 312 (7023): 71–72.. 2. Федеральный закон от 21.11.2011 № 323-ФЗ (ред. от 03.04.2017) «Об основах охраны здоровья граждан в Российской Федерации».. 3. Эпидемиологический словарь, 4-е издание. Под ред. Джона М. Ласта для Международной эпидемиологической ассоциации. М., 2009. 316 с.. 4. Федеральное агентство по техническому регулированию и метрологии. Национальный стандарт Российской Федерации. ГОСТР 52379-2005. Надлежащая клиническая практика. Москва, 2005. 5. Федеральный закон от 12.04.2010 № 61-ФЗ (ред. от 03.07.2016) «Об обращении лекарственных средств».. 6. Малая медицинская энциклопедия. М.: Медицинская энциклопедия, 1991— 96 гг. [Электронный ресурс]. Режим доступа:http://dic.academic.ru/dic.nsf/enc_medicine/28878/Синдром. 7. Андреева Н. С., Реброва О. Ю., Зорин Н. А. и др. Системы оценки достоверности научных доказательств и убедительности рекомендаций: сравнительная характеристика и перспективы унификации. Медицинские технологии. Оценка и выбор. 2012. №. 4. С. 10–24.. 8. Кухарчук В. В. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр //Атеросклероз и дислипидемии. – 2020. – Т. 11. – №. 1 (38).. 9. Nordestgaard B. G. et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society, //European heart journal. – 2013. – Т. 34. – №. 45. – С. 3478-3490.. 10. Yao Z. Human apolipoprotein C-III — a new intrahepatic protein factor promoting assembly and secretion of very low density lipoproteins. Cardiovasc Hematol Disord Drug Targets. 2012;12(2):133-140.. 11. Sacks FM, Alaupovic P, Moye LA, et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 2000;102:1886-1892. 12. Hegele R.A., Ginsberg H.N., Chapman M.J., et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014. 2(8): 655-666. doi: 10.1016/S2213-8587(13)70191-8. 13. Метельская В. А. и др. Анализ распространенности показателей, характеризующих атерогенность спектра липопротеидов, у жителей Российской Федерации (по данным исследования ЭССЕ-РФ) //Профилактическая медицина. – 2016. – Т. 19. – №. 1. – С. 15-23.. 14. Caggiula A. W. et al. The multiple risk factor intervention trial (MRFIT): IV. Intervention on blood lipids //Preventive Medicine. – 1981. – Т. 10. – №. 4. – С. 443-475.. 15. Castelli W.P. Epidemiology of triglycerides: A view from Framingham. Am J Cardiol. 1992. 70(19): H3-H9. doi: 10.1016/0002-9149(92)91083-g. 16. Carey V. J. et al. Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of lowdensity lipoprotein cholesterol control //The American journal of cardiology. –, 2010. – Т. 106. – №. 6. – С. 757-763.. 17. Barter P., Gotto A.M., LaRosa J.C., et al. HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events. New England Journal of Medicine. 2007. 357(13): 1301-1310. doi: 10.1056/nejmoa064278. 18. Aguiar C. et al. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate–statin combination therapy //Atherosclerosis Supplements. – 2015., – Т. 19. – С. 1-12.. 19. Prospective Studies Collaboration et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths //The Lancet. – 2007. – Т. 370. – №. 9602. – С. 1. 20. Catapano A. L. et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. // Eur Heart J.– 2016. – Т. 37. – №. 39. – С. 2999-3058. Проект 53 21. Holewijn S. et al. Apolipoprotein B, non‐ HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk //Journal of internal medicine. – 2010. – Т. 268. – №. 6. – С. 567-577.. 22. Boekholdt S. M. et al. Association of LDL cholesterol, non–HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis //Jama. – 2012. – Т. 307. – №. 12. – С. 1302-1309.. 23. Langsted A., Nordestgaard B.G. Nonfasting versus fasting lipid profile for cardiovascular risk prediction. Pathology. 2019. 51(2): 131-141. doi: 10.1016/j.pathol.2018.09.062. 24. Farukhi Z., Mora S. The Future of Low-Density Lipoprotein Cholesterol in an Era of Nonfasting Lipid Testing and Potent Low-Density Lipoprotein Lowering. Circulation. 2018. 137(1): 20-23. doi: 10.1161/CIRCULATIONAHA.117.031857. 25. Meijboom W.B., Meijs M.F., Schuijf J.D., et al. Diagnostic accuracy of 64-slice computed tomography coronary angiography: a prospective, multicenter, multivendor study. J Am Coll Cardiol. 2008. 52(25): 2135-2144. doi: 10.1016/j.jacc.2008.08.058. 26. Agatston A.S., Janowitz W.R., Hildner F.J., et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990. 15(4): 827-832. doi: 10.1016/0735-1097(90)90282-t. 27. Serrano C.V., de Mattos F.R., Pitta F.G., et al. Association between NeutrophilLymphocyte and Platelet-Lymphocyte Ratios and Coronary Artery Calcification Score among Asymptomatic Patients: Data from a Cross-Sectional Study. Mediators Inflamm. 2019., 2019: 1- 8. doi: 10.1155/2019/6513847. 28. Piepoli M. F. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice, (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) //European heart journal. – 2016. – Т. 37. – №. 29. – С. 231. 29. Mortensen M.B., Falk E., Li D., et al. Statin Trials, Cardiovascular Events, and Coronary Artery Calcification. JACC: Cardiovascular Imaging. 2018. 11(2): 221-230. doi: 10.1016/j.jcmg.2017.01.029. 30. McDermott M.M., Kramer C.M., Tian L., et al. Plaque Composition in the Proximal Superficial Femoral Artery and Peripheral Artery Disease Events. JACC: Cardiovascular Imaging. 2017. 10(9): 1003-1012. doi: 10.1016/j.jcmg.2016.08.012. 31. Sillesen H., Sartori S., Sandholt B., et al. Carotid plaque thickness and carotid plaque burden predict future cardiovascular events in asymptomatic adult Americans. European Heart Journal - Cardiovascular Imaging. 2017. 19(9): 1042-1050. doi: 10.1093/ehj. 32. Perrone-Filardi P., Achenbach S., Mohlenkamp S., et al. Cardiac computed tomography and myocardial perfusion scintigraphy for risk stratification in asymptomatic individuals without known cardiovascular disease:, a position statement of the Working Group on Nuclear Cardiology and Cardiac CT of the European Society of Cardiology //European heart journal. – 2011. – Т. 32. – №. 16. – С. 1986-1993.. 33. Den Ruijter H.M., Peters S.A.E., Anderson T.J., et al. Common Carotid IntimaMedia Thickness Measurements in Cardiovascular Risk Prediction. JAMA. 2012. 308(8): 796- 803. doi: 10.1001/jama.2012.9630. 34. Inaba Y., Chen J. A., Bergmann S. R. Carotid plaque, compared with carotid intima-media thickness, more accurately predicts coronary artery disease events: a meta-analysis //Atherosclerosis. – 2012. – Т. 220. – №. 1. – С. 128-133.. 35. Lorenz M. W. et al. Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a metaanalysis of individual participant data //The Lancet. – 2012. – Т. 379. – №. 9831., С. 2053-2062.. 36. Pletcher M. J. et al. Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis //Archives of internal medicine. – 2004. – Т. 164. – №. 12. – С. 1285-1292.. 37. Akioyamen L. E. et al. Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: A systematic review and meta-analysis //Journal of clinical lipidology. – 2019. – Т. 13. – №. 1. – С. 15-30.. 38. Cannon C. P. et al. Ezetimibe added to statin therapy after acute coronary syndromes //New England Journal of Medicine. – 2015. – Т. 372. – №. 25. – С. 2387-2397.. 39. Trialists C. T. et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials //The Lancet. – 2015. – Т. 385. – №. 9976. – С. 1397-1405.. Проект 55 40. Sabatine M. S. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease //New England Journal of Medicine. – 2017. – Т. 376. – №. 18. – С. 1713-1722.. 41. Jukema J. W. et al. ODYSSEY OUTCOMES Committees and Investigators. Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial //J Am Coll Cardiol. – 2019. – Т. 74. – №. 9. – С. 1167-1176.. 42. Trialists C. T. et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials //The Lancet. – 2012. – Т. 380. – №. 9841. – С. 581-590.. 43. Santos R. D. et al. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel //, The lancet Diabetes & endocrinology. – 2016. – Т. 4. – №. 10. – С. 850-861.. 44. Eckel R.H., Jakicic J.M., Ard J.D., et al. 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk. Circulation. 2013. 129(25 suppl 2): S76-S99. doi: 10.1161/01.cir.0000437740.48606.d1. 45. de Lorgeril M., Salen P., Martin J.-L., et al. Mediterranean Diet, Traditional Risk Factors, and the Rate of Cardiovascular Complications After Myocardial Infarction. Circulation. 1999. 99(6): 779-785. doi: 10.1161/01.cir.99.6.779. 46. Estruch R., Ros E., Salas-Salvado J., et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med. 2018. 378(25): e34. doi: 10.1056/NEJMoa1800389. 47. Mozaffarian D., Lemaitre R.N., King I.B., et al. Plasma Phospholipid Long-Chain ω-3 Fatty Acids and Total and Cause-Specific Mortality in Older Adults. Ann Intern Med. 2013. 158(7): 515-525. doi: 10.7326/0003-4819-158-7-201304020-00003. 48. Lu Z., Kou W., Du B., et al. Effect of Xuezhikang, an Extract From Red Yeast Chinese Rice, on Coronary Events in a Chinese Population With Previous Myocardial Infarction. Am J Cardiol. 2008. 101(12): 1689-1693. doi: 10.1016/j.amjcard.2008.02.056. 49. Li Y., Jiang L., Jia Z., et al. A Meta-Analysis of Red Yeast Rice: An Effective and Relatively Safe Alternative Approach for Dyslipidemia. PLoS One. 2014. 9(6): e98611. doi: 10.1371/journal.pone.0098611. Проект 56 50. Mach F., Baigent C., Catapano A.L., et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019. doi: 10.1093/eurheartj/ehz455. 51. Taylor F., Huffman M.D., Macedo A.F., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews. 2013. doi: 10.1002/14651858.cd004816.pub5. 52. Sever P.S., Dahlöf B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—, Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. The Lancet. 2003. 361(9364): 1149-1158. doi: 10.1016/s0140-6736(03)12948-0. 53. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. The Lancet., 2004. 364(9435): 685-696. doi: 10.1016/s0140-6736(04)16895-5. 54. Schwartz G.G. Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary SyndromesThe MIRACL Study: A Randomized Controlled Trial. JAMA. 2001. 285(13): 1711. doi: 10.1001/jama.285.13.1711. 55. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004. 350(15): 1495-1504. doi: 10.1056/NEJMoa040583. 56. Patti G., Pasceri V., Colonna G., et al. Atorvastatin Pretreatment Improves Outcomes in Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention. J Am Coll Cardiol. 2007. 49(12): 1272-1278. doi: 10.1016/j.jacc.2007.02.025. 57. Shepherd J., Kastelein J.J., Bittner V., et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008. 51(15): 1448-1454. doi: 10.101. 58. Athyros V.G., Papageorgiou A.A., Mercouris B.R., et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart- disease, Evaluation (GREACE) study. Curr Med Res Opin. 2002. 18(4): 220-228. doi: 10.1185/030079902125000787. 59. Amarenco P., Bogousslavsky J., Callahan A., 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006. 355(6): 549-559. doi: 10.1056/NEJMoa061894. 60. Newman C.B., Palmer G., Silbershatz H., et al. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol. 2003. 92(6): 670-676. doi: 10.1016/s0002-9149(03)00820-8. 61. Boekholdt S.M., Hovingh G.K., Mora S., et al. Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events. J Am Coll Cardiol. 2014. 64(5): 485-494. doi: 10.1016/j.jacc.2014.02.615. 62. Fruchart J.C., Duriez P. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs of Today. 2006. 42(1): 39. doi: 10.1358/dot.2006.42.1.963528. 63. Keating G.M., Croom K.F. Fenofibrate. Drugs. 2007. 67(1): 121-153. doi: 10.2165/00003495-200767010-00013. 64. Group S.C. Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J. 2010. 160(5): 785-794.e710. doi: 10.1016/j.ahj.201. 65. Abifadel M., Varret M., Rabès J.-P., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003. 34(2): 154-156. doi: 10.1038/ng1161. 66. Norata G.D., Tibolla G., Catapano A.L. Targeting PCSK9 for Hypercholesterolemia. Annual Review of Pharmacology and Toxicology. 2014. 54(1): 273-293. doi: 10.1146/annurev-pharmtox-011613-140025. 67. Giugliano R. P. et al. Clinical efficacy and safety of achieving very low LDLcholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial //The Lancet. – 2017. – Т. 390. – №. 10106. – С. 1962-1971. 68. Bhatt D. L. et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia //New England Journal of Medicine. – 2019. – Т. 380. – №. 1. – С. 11-22.. Проект 58 69. Brugts J. J. et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials //Bmj. – 2009. – Т. 338.. 70. Mills E. J. et al. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients //Journal of the American College of Cardiology. – 2008. – Т. 52. – №. 22. – С. 1769-1781.. 71. Moriarty P. M. et al. Efficacy and safety of alirocumab vs ezetimibe in statinintolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial //Journal of clinical lipidology. – 2015. – Т. 9. – №. 6. – С. 758-769.. 72. Nissen S. E. et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial //Jama. – 2016. – Т. 315. – №. 15. – С. 1580-1590.. 73. Schreml J., Gouni-Berthold I. Role of anti-PCSK9 antibodies in the treatment of patients with statin intolerance //Current medicinal chemistry. – 2018. – Т. 25. – №. 13. – С. 1538-1548.. 74. Landmesser U. et al. European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk //, European Heart Journal. – 2017. – Т. 38. – №. 29. – С. 2245-2255.. 75. Ridker P. M. et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients //New England Journal of Medicine. – 2017. – Т. 376. – №. 16. – С. 1527-1539.. 76. Vallejo-Vaz A. J. et al. Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial //Circulation. – 2018. – Т. 138. – №. 8. – С. 770-781.. 77. Chapman M. J. et al. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk //Pharmacology & therapeutics. – 2010. – Т. 126. – №. 3. – С. 314-345.. 78. ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus //New England Journal of Medicine. – 2010. – Т. 362. – №. 17. – С. 1563-1574.. Проект 59 79. FIELD Study Investigators et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial //The Lancet. – 2005. – Т. 366. – №. 9500. – С. 1849-1861.. 80. Doll R. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis //Lancet. – 2008. – Т. 371. – №. 9607. – С. 117- 125.. 81. Nicholls S. J. et al. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials //Journal of the American College of Cardiology. – 2008. – Т. 52. – №. 4. – С. 255-262.. 82. Laing S. P. et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes //Diabetologia. – 2003. – Т. 46. – №. 6. – С. 760-765.. 83. Giugliano R. P. et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) //, Circulation. – 2018. – Т. 137. – №. 15. – С. 1571-1582.. 84. Zinman B., Wanner C., Lachin J.M., et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2015. 373(22): 2117-2128.. 85. Marso S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes //New England Journal of Medicine. – 2016. – Т. 375. – №. 4. – С. 311-322.. 86. Marso S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes //N Engl J Med. – 2016. – Т. 375. – С. 1834-1844.. 87. McGuire D. K. et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis //JAMA cardiology. – 2020.. 88. McGuire D. K. et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis //JAMA cardiology. – 2020.. 89. UK Prospective Diabetes Study (UKPDS) Group et al. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) //The Lancet. – 1998. – Т. 352. – №. 9131. – С. 854-865.. Проект 60 90. Franczyk-Skora B. et al. Acute coronary syndromes in patients with chronic kidney disease //Current vascular pharmacology. – 2013. – Т. 11. – №. 5. – С. 758-767.. 91. Loncar G. et al. Impact of renal failure on all-cause mortality and other outcomes in patients treated by percutaneous coronary intervention //Archives of Cardiovascular Diseases. – 2015. – Т. 108. – №. 11. – С. 554-562.. 92. Herrington W. et al. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials //Lancet Diabetes and Endocrinology. – 2016. – Т. 4. – №. 10.. 93. Baigent C. et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial //The Lancet. – 2011. – Т. 377. – №. 9784. – С., 2181-2192.. 94. Barylski M. et al. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy—a meta-analysis of 11 randomized controlled trials involving 21,295 participants //Pharmacological research. – 2013. – Т. 72. – С. 35-44.. 95. Palmer S. C. et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis //Cochrane Database of Systematic Reviews. – 2014. – №. 5.. 96. Sun L. et al. Meta-analysis of statin therapy in maintenance dialysis patients //Renal Failure. – 2015. – Т. 37. – №. 7. – С. 1149-1156.. 97. Green D., Ritchie J. P., Kalra P. A. Meta-analysis of lipid-lowering therapy in maintenance dialysis patients //Nephron Clinical Practice. – 2013. – Т. 124. – №. 3-4. – С. 209- 217.. 98. Lin Y. C. et al. Effects and Safety of Statin and Ezetimibe Combination Therapy in Patients with Chronic Kidney Disease: A Systematic Review and Meta‐ Analysis //Clinical Pharmacology & Therapeutics. – 2020.. 99. Wanner C. et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis //New England Journal of Medicine. – 2005. – Т. 353. – №. 3. – С. 238-248.. 100. Fellström B. C. et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis //New England Journal of Medicine. – 2009. – Т. 360. – №. 14. – С. 1395-1407.. 101. de Lemos J. A. et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial //Jama. – 2004. – Т. 292. – №. 11. – С. 1307-1316.. 102. Ray K. K. et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial //Journal of the American College of Cardiology. – 2005. – Т. 46. – №. 8. – С. 1405-1410.. 103. Schwartz G. G. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial //Jama. – 2001. – Т. 285. – №. 13. – С. 1711-1718.. 104. Koskinas K. C. et al. Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS) //Journal of the American College of Cardiology. – 2019. – Т. 74. – №. 20. – С. 2452-2462.. 105. Trankle C. R. et al. Alirocumab in acute myocardial infarction: results from the Virginia commonwealth university alirocumab response trial (VCU-AlirocRT) //Journal of cardiovascular pharmacology. – 2019. – Т. 74. – №. 3. – С. 266-269.. 106. Armitage J. et al. Efficacy and safety of statin therapy in older people: a metaanalysis of individual participant data from 28 randomised controlled trials //The Lancet. – 2019. – Т. 393. – №. 10170. – С. 407-415.. 107. Taskinen M. R. et al. Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity //Journal of internal medicine. – 2017. – Т. 282. – №. 2. – С. 187-201.. 108. Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes //New England journal of medicine. – 2013. – Т. 369. – №. 2. – С. 145-154.. 109. Batsis J. A. et al. Weight loss interventions in older adults with obesity: a systematic review of randomized controlled trials since 2005 //Journal of the American Geriatrics Society. – 2017. – Т. 65. – №. 2. – С. 257-268.. 110. Khader Y. S. et al. Oral contraceptives use and the risk of myocardial infarction: a meta-analysis //Contraception. – 2003. – Т. 68. – №. 1. – С. 11-17.. Проект 62 111. Shufelt C. L., Merz C. N. B. Contraceptive hormone use and cardiovascular disease //Journal of the American College of Cardiology. – 2009. – Т. 53. – №. 3. – С. 221-231.. 112. Manson J. A. E. et al. Estrogen plus progestin and the risk of coronary heart disease //New England Journal of Medicine. – 2003. – Т. 349. – №. 6. – С. 523-534.. 113. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack //New England Journal of Medicine. – 2006. – Т. 355. – №. 6. – С. 549-559.. 114. Amarenco P., Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention //The Lancet Neurology. – 2009. – Т. 8. – №. 5. – С. 453-463.. 115. Chan K. et al. Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial //Circulation. – 2010. – Т. 121. – №. 2. – С. 306-314. 116. Cowell S. J. et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis //New England Journal of Medicine. – 2005. – Т. 352. – №. 23. – С. 2389-2397.. 117. Dichtl W. et al. Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg) //The American journal of cardiology. – 2008. – Т. 102. – №. 6. – С. 743-748.. 118. Rossebø A. B. et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis //New England journal of medicine. – 2008. – Т. 359. – №. 13. – С. 1343-1356.. 119. Kelley G. A., Kelley K. S., Tran Z. V. Walking, lipids, and lipoproteins: a metaanalysis of randomized controlled trials //Preventive medicine. – 2004. – Т. 38. – №. 5. – С. 651- 661.. 120. Hardman A. E. Physical activity, obesity and blood lipids //International Journal of Obesity. – 1999. – Т. 23. – №. 3. – С. S64-S71.. 121. Tran Z. V. et al. The effects of exercise on blood lipids and lipoproteins: a metaanalysis of studies //Med Sci Sports Exerc. – 1983. – Т. 15. – №. 5. – С. 393-402.. Проект 63 122. Mozaffarian D., Micha R., Wallace S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials //PLoS Med. – 2010. – Т. 7. – №. 3. – С. e1000252.. 123. Mozaffarian D., Aro A., Willett W. C. Health effects of trans-fatty acids: experimental and observational evidence //European journal of clinical nutrition. – 2009. – Т. 63. – №. 2. – С. S5-S21.. 124. Clifton P. M., Keogh J. B. A systematic review of the effect of dietary saturated and polyunsaturated fat on heart disease //Nutrition, Metabolism and Cardiovascular Diseases. – 2017. – Т. 27. – №. 12. – С. 1060-1080.. 125. Brown L. et al. Cholesterol-lowering effects of dietary fiber: a meta-analysis //The American journal of clinical nutrition. – 1999. – Т. 69. – №. 1. – С. 30-42.. 126. Hollænder P. L. B., Ross A. B., Kristensen M. Whole-grain and blood lipid changes in apparently healthy adults: a systematic review and meta-analysis of randomized controlled studies– //The American journal of clinical nutrition. – 2015. – Т. 102. – №. 3., – С. 556-572.. 127. Gylling H. et al. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease //Atherosclerosis. – 2014. – Т. 232. – №. 2. – С. 346-360.. 128. Musa-Veloso K. et al. A comparison of the LDL-cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: results of a meta-analysis of randomized, placebo-controlled trials /, /Prostaglandins, Leukotrienes and Essential Fatty Acids. – 2011. – Т. 85. – №. 1. – С. 9-28.. 129. Poli A. et al. Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper //Pharmacological research. – 2018. – Т. 134. – С. 51-60.. 130. Li Y. et al. A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia //PloS one. – 2014. – Т. 9. – №. 6. – С. e98611.. 131. Nordmann A. J. et al. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials //Archives of internal medicine. – 2006. – Т. 166. – №. 3. – С. 285-293.. 132. Zomer E. et al. Interventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta‐ analysis //Obesity reviews. – 2016. – Т. 17. – №. 10. – С. 1001-1011.. 133. Berger S. et al. Dietary cholesterol and cardiovascular disease: a systematic review and meta-analysis //The American journal of clinical nutrition. – 2015. – Т. 102. – №. 2. – С. 276-294.. 134. Griffin J. D., Lichtenstein A. H. Dietary cholesterol and plasma lipoprotein profiles: randomized controlled trials //Current nutrition reports. – 2013. – Т. 2. – №. 4. – С. 274-282.. 135. Shaw K. et al. Exercise for overweight or obesity. Cochrane Database Syst Rev 2006; CD003817. – 2013.. 136. Droste D. W. et al. A daily glass of red wine associated with lifestyle changes independentlyimproves blood lipids in patients with carotid arteriosclerosis: results from arandomized controlled trial //Nutrition journal. – 2013. – Т. 12. – №. 1. – С. 147.. 137. Rimm E. B. et al. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors //Bmj. – 1999. – Т. 319. – №. 7224. – С. 1523-1528.. 138. Yu-Poth S. et al. Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis //The American journal of clinical nutrition. – 1999. – Т. 69. – №. 4. – С., 632-646.. . 139. Santos F. L. et al. Systematic review and meta‐ analysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk factors //Obesity Reviews. – 2012. – Т. 13. – №. 11. – С. 1048-1066.. 140. Rivellese A. A. et al. Effects of dietary saturated, monounsaturated and n-3 fatty acids on fasting lipoproteins, LDL size and post-prandial lipid metabolism in healthy subjects //Atherosclerosis. – 2003. – Т. 167. – №. 1. – С. 149-158.. 141. Wei M. Y., Jacobson T. A. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis //Current atherosclerosis reports. – 2011. – Т. 13. – №. 6. – С. 474-483. Проект 65 142. Kelishadi R., Mansourian M., Heidari-Beni M. Association of fructose consumption and components of metabolic syndrome in human studies: a systematic review and meta-analysis //Nutrition. – 2014. – Т. 30. – №. 5. – С. 503-510. 143. Stanhope K. L. et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans //The Journal of clinical investigation. – 2009. – Т. 119. – №. 5. –, С. 1322-1334.. 144. Gayet-Boyer C. et al. Is there a linear relationship between the dose of ruminant trans-fatty acids and cardiovascular risk markers in healthy subjects: results from a systematic review and meta-regression of randomised clinical trials //, British Journal of Nutrition. – 2014. – Т. 112. – №. 12. – С. 1914-1922.. 145. Kelley G. A., Kelley K. S. Impact of progressive resistance training on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials //Preventive medicine. – 2009. – Т. 48. – №. 1. – С. 9-19.. 146. Kastorini C. M. et al. The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals //Journal of the American college of cardiology. – 2011. – Т. 57. – №. 11. – С. 1299-1313.. 147. Maeda K., Noguchi Y., Fukui T. The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis //Preventive medicine. – 2003. – Т. 37. – №. 4. – С. 283-290.. 148. Mark L. et al. Effects of ezetimibe on lipids and lipoproteins in patients with hypercholesterolemia and different apolipoprotein E genotypes //Current medical research and opinion. – 2007. – Т. 23. – №. 7. – С. 1541-1548.. 149. Li Y. H. et al. 2017 Taiwan lipid guidelines for high risk patients //Journal of the Formosan Medical Association. – 2017. – Т. 116. – №. 4. – С. 217-248.. 150. Robinson J. G. et al. Eradicating the burden of atherosclerotic cardiovascular disease by lowering apolipoprotein B lipoproteins earlier in life //Journal of the American Heart Association. – 2018. – Т. 7. – №. 20. – С. e009778.. 151. Wilson D. P. et al. Use of Lipoprotein (a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association //Journal of clinical lipidology. – 2019. – Т. 13. – №. 3. – С. 374-392. Проект 66 152. Мешков А.Н. и др. Распределение показателей липидного спектра у мужчин и женщин трудоспособного возраста в Российской Федерации: результаты исследования эссе-РФ за 2012-2014гг // Кардиоваскулярная терапия и профилактика. – 2017. – Т. 16. – № 4. – С. 62-67. 153. Болезни сердца по Браунвальду: руководство по сердечно-сосудистой медицине / Под ред. П. Либби и др. ; пер. с англ., под общ. ред. Р.Г. Оганова. В 4 т. Том 1: — М.: Логосфера, 2012. — 596 с.: ил.; 21,6 см. — Перевод изд. Braunwald’s heart disease: a textbook of cardiovascular medicine, Peter Libby, et al., 8th ed. 154. The Merck manual of diagnosis and therapy: справочное издание / ed.: M. H.Beers [et. al]. - 17th ed. - XXXIII, 2833 p. : il. - Index.: p. 2657-2833. - ISBN 0911910-10-7. 155. Lawler PR, et al. Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies // Eur Heart J. 2020 Jan 1;41(1):86-94. 156. Liu J. et al. Effects of blood triglycerides on cardiovascular and all-cause mortality: a systematic review and meta-analysis of 61 prospective studies //Lipids in health and disease. – 2013. – Т. 12. – №. 1. – С. 1-11. 157. Kosmas CE, Estrella AM, Sourlas A et al. Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia. 158. Levin AA. Treating disease ath the RNA levek with oligonucleotides. NEJM 2019;380:57-70. 159. Tsouka AN, Tellis CC, Tseplis AD. Pharmacology of PCK9 Inhibitors: current status and future perspectives. Current Pharmaceutical Design 2018;24:3622-3633. 160. Wang N, Tall AR. New approach to PCSK9 therapeutics. NEJM 2017; 376:41-51. 161. Ray KK, Phill M, Scot Wright R et al. Two phase 3 trials of Inclisiran in patients with elevated LDL cholesterol. NEJM 2020;382:1507-1519 162. Raal JF, Kallend D, Ray KK et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. NEJM 2020; 382:1520-1530. 163. Marston NA, Giugliano RP, Im K, Silverman MG, O'Donoghue ML, Wiviott SD, Ference BA, Sabatine MS. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. Circulation. 2019 Oct 15;140(16):1308-1317. Проект 67 164. Rohit D and Shankar J. Comparative Study of Atorvastatin and Rosuvastatin in Combination with Fenofibrate in mixed Hyperlipidemia. Int J Pharmacol and Clin Sci. 2016;5(1):25-31. 165. Bangalore S, Kamalakkannan G, Parkar S, Messerli F H. Fixed-dose combinations improve medication compliance: a meta-analysis. American Journal of Medicine 2007; 120(8): 713-719. 166. Baumgartner, Ana; Drame, Katarina; Geutjens, Stijn; Airaksinen, Marja (2020). Does the Polypill Improve Patient Adherence Compared to Its Individual Formulations? A Systematic Review. Pharmaceutics, 12(2), 190–. 167. Cholesterol Treatment Trialists Collaboration, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a metaanalysis. Lancet 2008;371:117-125. 168. Bouzidi N. et al. Effects of omega-3 polyunsaturated fatty-acid supplementation on redox status in chronic renal failure patients with dyslipidemia //Journal of renal nutrition. – 2010. – Т. 20. – №. 5. – С. 321-328. 169. Svensson M. et al. The effect of n-3 fatty acids on plasma lipids and lipoproteins and blood pressure in patients with CRF //American journal of kidney diseases. – 2004. – Т. 44. – №. 1. – С. 77-83 170. Li W. L. et al. Dietary Omega-3 Fatty Acid Intake and Mortality in CKD Population: A 1999–2014 NHANES Analysis //American Journal of Nephrology. – 2021. – С. 1-10 171. Navarese EP, Kowalewski M, Andreotti F, van Wely M, Camaro C, Kolodziejczak M, Gorny B, Wirianta J, Kubica J, Kelm M, de Boer MJ, Suryapranata H. Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 2014;113:1753_1764. 172. Visseren FLJ, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-3337. 173. Anthonisen N. R. et al. The effects of a smoking cessation intervention on 14.5- year mortality: a randomized clinical trial // Ann Intern Med. - 2005. - Т. 142. - № 4. - С. 233-239. 174. Hughes J. R. et al. Antidepressants for smoking cessation // Cochrane Database Syst Rev. - 2007. № 1. - С. CD000031. 175. Lindson N. et al. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation // Cochrane Database Syst Rev. - 2019. - Т. 4. - № 4. - С. CD013308. Проект 68 176. Hu Y. et al. Smoking Cessation, Weight Change, Type 2 Diabetes, and Mortality. // N Engl J Med. - 2018. - Т. 379. - № 7. - С. 623-632. 177. Kavousi M. et al. Electronic cigarettes and health with special focus on cardiovascular effects: position paper of the European Association of Preventive Cardiology (EAPC) // Eur J Prev Cardiol. - 2020. - 2047487320941993. 178. Powell K. E. et al. The Scientific Foundation for the Physical Activity Guidelines for Americans, 2nd Edition // J Phys Act Health. - 2018. - С. 1-11. 179. Hupin D. et al. Even a low-dose of moderate-to-vigorous physical activity reduces mortality by 22% in adults aged >/=60 years: a systematic review and meta-analysis // Br J Sports Med. - 2015. - Т. 49. - № 19. - С. 1262-1267. 180. Sacks F. M. et. al. American Heart Association. Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association // Circulation. - 2017. - Т. 136. - № 10. - С. e1e23. 181. He F. J. et. al. Salt Reduction to Prevent Hypertension and Cardiovascular Disease: JACC State-of-the-Art Review // J Am Coll Cardiol. - 2020. - Т. 75. - № 6. - С. 632-647. 182. World Health Organization. A healthy diet sustainably produced. https://apps. who.int/iris/bitstream/handle/10665/278948/WHO-NMH-NHD-18.12-eng.pdf? ua=1 (21 July 2020). 183. Zhong V. W. et. al. Associations of Processed Meat, Unprocessed Red Meat, Poultry, or Fish Intake With Incident Cardiovascular Disease and AllCause Mortality // JAMA Intern Med. - 2020. - Т. 180. - № 6. - С.503-512. 184. World Health Organization. Guideline: sugars intake for adults and children. https://www.who.int/publications/i/item/9789241549028 (21 July 2020). 185. Wood A. M. et. al. Emerging Risk Factors Collaboration/EPIC-CVD/UK Biobank Alcohol Study Group. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies // Lancet. - 2018. - Т. 391. - № 10129. С.1513-1523. 186. Wing R. R. et. al. Association of Weight Loss Maintenance and Weight Regain on 4-Year Changes in CVD Risk Factors: the Action for Health in Diabetes (Look AHEAD) Clinical Trial // Diabetes Care. - 2016. - Т. 39 - № 12. - С. 1345-1355. 187. Cardoso L. et. al. Short- and long-term mortality after bariatric surgery: A systematic review and meta-analysis // Diabetes Obes Metab. - 2017. Т. 19. - № 9. - С. 1223-1232. 188. Sattar N. et. al. HbA1c in type 2 diabetes diagnostic criteria: addressing the right questions to move the field forwards // Diabetologia. - 2012. - Т. 55.- № 6. - С. 1564- 1567. 189. ADVANCE Collaborative Group et. al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes // N Engl J Med. - 2008. - Т. 358. - № 24. - С. 2560-2572. 190. Ettehad D. et. al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis // Lancet. - 2016. - Т. 387. - № 10022. - С. 957-967. 191. SPRINT Research Group et. al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control // N Engl J Med. - 2015. - Т. 373. - № 22. - С. 2103-2116. 192. Williamson J. D. et. al. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged >/=75 Years: A Randomized Clinical Trial // JAMA. - 2016. - Т. 315. - № 24. - С. 2673-2682. 193. Thomopoulos C. et. al. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials // J Hypertens. - 2016. - Т. 34. - № 4. С. 613-622. 194. Antithrombotic Trialists’ (ATT) Collaboration et. al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials // Lancet. - 2009. - Т. 373. - № 9678. - С.1849- 1860. 195. Cosentino F. et. al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD // Eur Heart J. - 2020. - Т. 41. - № 2. - С. 255-323. 196. Armenian S. H. et. al. Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study // J Clin Oncol. – 2016. - Т. 34. - № 10. – С. 1122–1130. 197. Chen W. et. al. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis // Lancet Respir Med. – 2015. – Т. 3. - № 8. – С. 631–639. 198. Ogdie A. et. al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study // Ann Rheum Dis. – 2015. - Т. 74. - № 2. – С. 326–332. Проект 70 199. Badran M. et. al. Epidemiology of Sleep Disturbances and Cardiovascular Consequences // Can J Cardiol. – 2015. – Т. 31. - № 7. – С. 873–879. 200. Zhao B. Et. al. Does erectile dysfunction independently predict cardiovascular events? It's time to act on the evidence // Eur J Prev Cardiol. – 2018. Т. 25. - № 12. – С. 1307–1311. 201. Visseren FLJ. et al., ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice// Eur Heart J. – 2021. - T. 42(34). – C.3227-3337 202. Приказ Министерства здравоохранения РФ от 29 марта 2019 г. N 173н "Об утверждении порядка проведения диспансерного наблюдения за взрослыми" 203. Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, Béjot Y et al. A comparison of two LDL cholesterol targets after ischemic stroke. N Engl J Med. 2020;382(1):9. doi:10.1056/ NEJMoa1910355 204. Cholesterol Treatment Trialists Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a metaanalysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:16701681 205. Cholesterol Treatment Trialists Collaboration, Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.Lancet2015;385:13971405 206. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, et al; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med.2018;379:2097–2107. doi: 10.1056/NEJMoa1801174 207. Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther. 2010 Apr;35(2):139-51. doi: 10.1111/j.1365-2710.2009.01085.x. PMID: 20456733 208. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532-61 209. Group HPSC. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people Проект 71 with peripheral arterial disease and other high-risk conditions. J Vasc Surg. 2007;45:645- 54; discussion 53-4 210. Koren MJ, Hunninghake DB. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol. 2004;44:1772-9 211. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;287:3215-22 212. Bohula EA, Wiviott SD, Giugliano RP, Blazing MA, Park JG, Murphy SA, White JA, Mach F, Van de Werf F, Dalby AJ, et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation.2017;136:2440–2450. doi: 10.1161/CIRCULATIONAHA.117.029095 213. Chiavaroli L, Nishi SK, Khan TA, Braunstein CR, Glenn AJ, Mejia SB, RahelićD, Kahleová H, Salas-Salvadó J, Jenkins DJA, et al. Portfolio dietary pattern and cardiovascular disease: a systematic review and metaanalysis of controlled trials. Prog Cardiovasc Dis.2018;61:43–53. doi: 10.1016/j.pcad.2018.05.004 214. Benner JS, Tierce JC, Ballantyne CM, Prasad C, Bullano MF, Willey VJ, Erbey J, Sugano DS. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics. 2004;22(suppl 3):13–23. doi: 10.2165/00019053-200422003-00003 215. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d’Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet2005;366:18491861 216. Aim-High Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.N Engl J Med2011;365:22552267. 217. Group HTC, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med2014;371:203212]. 218. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, et al. Helsinki Heart Study: primary-prevention Проект 72 trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987 Nov 12;317(20):1237-45. doi: 10.1056/NEJM198711123172001. PMID: 3313041 219. Lipids and lipoproteins in symptomatic coronary heart disease. Distribution, intercorrelations, and significance for risk classification in 6,700 men and 1,500 women. The Bezafibrate Infarction Prevention (BIP) Study Group, Israel. Circulation1992;86:839848 220. Defesche JC, Gidding SS, Harada-Shiba M, et al. Familial hypercholesterolaemia. Nat Rev Dis Primers. 2017 Dec 7;3:17093. doi: 10.1038/nrdp.2017.93. 221. Ershova AI, Meshkov AN, Bazhan SS, et al. The prevalence of familial hypercholesterolemia in the West Siberian region of the Russian Federation: A substudy of the ESSE-RF. PLoS One. 2017; 12 (7): e0181148. 222. Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014 Aug 21;35(32):2146-57. doi: 10.1093/eurheartj/ehu274. 223. Civeira F; International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis. 2004 Mar;173(1):55-68. doi: 10.1016/j.atherosclerosis.2003.11.010. 224. Кухарчук В.В., Малышев П.П., Мешков А.Н. Семейная гиперхолестеринемия: современные аспекты диагностики, профилактики и терапии. Кардиология. 2009;49(1):76-83. 225. Yuan G, Wang J, Hegele RA. Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. CMAJ. 2006 Apr 11;174(8):1124-9. doi: 10.1503/cmaj.051313. 226. Vuorio A, Docherty KF, Humphries SE, et al. Statin treatment of children with familial hypercholesterolemia - trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a consensus? Atherosclerosis. 2013 Feb;226(2):315-20. doi: 10.1016/j.atherosclerosis.2012.10.032. 227. Hopkins PN, Toth PP, Ballantyne CM, Rader DJ. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 Jun;5(3 Suppl):S9-17. doi: 10.1016/j.jacl.2011.03.452. 228. Myant NB. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia. Atherosclerosis. 1993 Dec;104(1-2):1- 18. doi: 10.1016/0021-9150(93)90171-p. 229. Meriño-Ibarra E, Castillo S, Mozas P, et al. Screening of APOB gene mutations in subjects with clinical diagnosis of familial hypercholesterolemia. Hum Biol. 2005 Oct;77(5):663-73. PMID: 16596945. 230. Мешков А.Н., Ершова А.И., Щербакова Н.В., и др. Фенотипические особенности течения гетерозиготной формы семейной гиперхолестеринемии у носителей мутаций генов LDLR и APOB. Кардиоваскулярная терапия и профилактика. 2011;10(8):63-65. 231. Burnett JR, Hooper AJ. Common and rare gene variants affecting plasma LDL cholesterol. Clin Biochem Rev. 2008 Feb;29(1):11-26. PMID: 18566665. 232. Мандельштам, М. Ю., Васильев В.Б. Моногенные гиперхолестеринемии: новые гены, новые мишени для лечения. Генетика. 2008;44(10):1309-1316/ 233. Шахтшнейдер Е.В., Иванощук Д.Е., Макаренкова К.В., и др. Каскадный генетический скрининг в диагностике гетерозиготной формы семейной гиперхолестеринемии: клинический случай. Российский кардиологический журнал 2017;146(6):178–179. 234. Abifadel M, Rabès JP, Devillers M, et al. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat. 2009 Apr;30(4):520-9. doi: 10.1002/humu.20882. 235. Ежов М.В., Бажан С.С., Ершова А.И., и др. Клинические рекомендации по семейной гиперхолестеринемии. Атеросклероз. 2019;15(1):58-98. 236. Wiegman A, Gidding SS, Watts GF, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015 Sep 21;36(36):2425-37. doi: 10.1093/eurheartj/ehv157. 237. Watts GF, Gidding S, Wierzbicki AS, et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation: executive summary. J Atheroscler Thromb. 2014;21(4):368-74. PMID: 24892180. 238. Marteau T, Senior V, Humphries SE, et al. Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: a randomized controlled trial. Am J Med Genet A. 2004 Jul 30;128A(3):285-93. doi: 10.1002/ajmg.a.30102. Проект 74 239. Civeira F, Ros E, Jarauta E, et al. Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia. Am J Cardiol. 2008 Nov 1;102(9):1187-93, 1193.e1. doi: 10.1016/j.amjcard.2008.06.056. 240. Palacios L, Grandoso L, Cuevas N, et al. Molecular characterization of familial hypercholesterolemia in Spain. Atherosclerosis. 2012 Mar;221(1):137-42. doi: 10.1016/j.atherosclerosis.2011.12.021. 241. European Heart Journal (2021) 1-111. 2021 esc Guidelines on cardiovascular disease prevention in clinical practice 242. Oscarsson J, Önnerhag K, Risérus U, Sundén M, Johansson L, Jansson PA, Moris L, Nilsson PM, Eriksson JW, Lind L. Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study. J Clin Lipidol. 2018 Nov-Dec;12(6):1390-1403.e4. doi: 10.1016/j.jacl.2018.08.003. Epub 2018 Aug 10. PMID: 30197273.